Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Bioxcel Therapeutics ( (BTAI) ).
On April 3, 2025, Bioxcel Therapeutics entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell shares of Common Stock through an ‘at the market offering’ as defined under the Securities Act of 1933. On August 18, 2025, the company filed a prospectus supplement with the SEC for the sale of up to $80 million in shares under this agreement. Honigman LLP provided a legal opinion on the validity of these shares, which was included in a Form 8-K filing. This filing does not constitute an offer to sell or solicitation to buy any securities in jurisdictions where it would be unlawful.
The most recent analyst rating on (BTAI) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
Average Trading Volume: 7,585,290
Technical Sentiment Signal: Hold
Current Market Cap: $79.77M
For detailed information about BTAI stock, go to TipRanks’ Stock Analysis page.